Reduction in the recurrence of meningiomas by combining somatostatin receptor scintigraphy of (99m)Tc-HYNIC-octreotide SPECT/CT and radio guidance with a hand-held γ-probe during surgery.

Abstract

PURPOSE:

The aim of this study was to determine whether recurrence of meningiomas could be reduced by combining somatostatin receptor scintigraphy (SRS) of Tc-HYNIC-octreotide SPECT/CT and radio guidance with a hand-held γ-probe during surgery.

MATERIALS AND METHODS:

Thirty patients with meningiomas diagnosed by MRI and considered as the study group were treated with Tc-HYNIC-octreotide SPECT/CT preoperatively and pathologically examined postoperatively. Another 60 patients considered as the control group underwent only an MRI preoperatively and a pathological examination postoperatively. For the patients in the study group, meningiomas were removed by a hand-held γ-probe 4-12 h after SRS; these patients were followed up by MRI examination each year for 5 years to monitor the recurrence rate of the meningiomas. For the control group, routine operations without radio guidance were performed and followed up with MRI examination simultaneously.

RESULTS:

All patients in the study group, comprising 20 with grade I and 10 with grade II meningiomas, showed high Tc-HYNIC-octreotide accumulation with a sensitivity of 100% for SRS; four patients (13.3%) relapsed after a 5-year follow-up, including one (5%) patient with a grade I and three (30%) patients with a grade II meningioma. However, among the 60 control patients, 30 were of grade I and 30 were of grade II; 18 patients (30%) experienced recurrence, including five (16.7%) grade I patients and 13 (43.3%) grade II patients. There were significant differences in recurrence between the study group and the control group when considering all the patients and those in grade I and grade II (all P values were below 0.001).

CONCLUSION:

Tc-HYNIC-octreotide SPECT/CT SRS is a sensitive technique for detecting meningiomas, and radio guidance using a hand-held γ-probe with Tc-HYNIC-octreotide during surgery can significantly reduce the recurrence of meningiomas.

• Authors: Shengjun Wang, Weidong Yang, Jinglan Deng, Jianning Zhang, Fucheng Ma, Jing Wang
• Journal: Nuclear medicine communications (Nucl Med Commun) Vol. 34 Issue 3 Pg. 249-53 (Mar 2013) ISSN: 1473-5628 [Electronic] England
• PMID: 23276828 (Publication Type: Journal Article)

Chemical References

• Organotechnetium Compounds
• Receptors, Somatostatin
• technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide
• Octreotide

Topics

• Adult
• Aged
• Aged, 80 and over
• Case-Control Studies
• Female
• Gamma Rays
• Humans
• Magnetic Resonance Imaging (methods)
• Male
• Meningioma (diagnostic imaging, prevention & control, therapy)
• Middle Aged
• Multimodal Imaging (methods)
• Neoplasm Recurrence, Local (prevention & control)
• Octreotide (analogs & derivatives, pharmacology)
• Organotechnetium Compounds (pharmacology)
• Positron-Emission Tomography
• Radiosurgery (methods)
• Receptors, Somatostatin (metabolism)
• Time Factors
• Tomography, X-Ray Computed